• LAST PRICE
    2.4800
  • TODAY'S CHANGE (%)
    Trending Down-0.0700 (-2.7451%)
  • Bid / Lots
    2.4000/ 4
  • Ask / Lots
    2.7500/ 10
  • Open / Previous Close
    2.5700 / 2.5500
  • Day Range
    Low 2.4400
    High 2.9500
  • 52 Week Range
    Low 1.0700
    High 9.2200
  • Volume
    560,491
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 2.55
TimeVolumeCGTX
09:32 ET61792.55
09:33 ET145202.6636
09:35 ET20002.65
09:37 ET3002.6584
09:42 ET34932.659
09:44 ET40002.6527
09:46 ET65002.6
09:48 ET23752.57
09:50 ET17802.61
09:51 ET59002.61
09:53 ET96742.6044
09:55 ET13352.6466
09:57 ET8002.64
10:00 ET7002.6342
10:02 ET30882.62
10:04 ET7002.62
10:08 ET13482.669
10:09 ET2002.6898
10:11 ET76802.6686
10:13 ET14002.7
10:15 ET57002.74
10:18 ET100362.7059
10:20 ET82302.7362
10:22 ET179502.7449
10:24 ET123812.8499
10:26 ET328502.9
10:27 ET206422.7401
10:29 ET21002.7701
10:31 ET35392.8099
10:33 ET62642.72
10:36 ET32002.75
10:38 ET59902.73
10:40 ET116702.69
10:42 ET187002.55
10:44 ET59002.6024
10:45 ET1502.647
10:47 ET5002.6466
10:49 ET53502.61
10:51 ET23002.63
10:54 ET66322.69
10:58 ET3502.6895
11:00 ET2002.681
11:02 ET35682.6714
11:03 ET80002.65
11:05 ET13772.67
11:12 ET19232.67
11:14 ET15002.665
11:16 ET1002.6699
11:20 ET5002.6699
11:23 ET13802.6588
11:25 ET17802.64
11:27 ET43702.6
11:32 ET5252.6353
11:34 ET6902.585
11:36 ET10002.5974
11:38 ET71672.5941
11:39 ET65022.63
11:41 ET4002.63
11:45 ET1002.6299
11:48 ET8002.63
11:54 ET17922.61
11:56 ET5002.6178
12:28 ET11002.63
12:30 ET100002.57
12:37 ET7002.61
12:46 ET1002.62
12:57 ET145952.68
01:02 ET21002.62
01:04 ET20002.65
01:06 ET6002.63
01:08 ET9972.61
01:09 ET8962.57
01:15 ET16002.61
01:18 ET75432.62
01:20 ET5002.62
01:24 ET3502.6238
01:26 ET11002.63
01:27 ET32982.62
01:31 ET1802.62
01:33 ET1002.61
01:38 ET8342.61
01:42 ET20502.6001
01:44 ET34842.6
01:45 ET89412.58
01:47 ET217282.55
01:49 ET81982.52
01:51 ET26502.55
01:58 ET127342.5401
02:00 ET19002.54
02:02 ET13002.56
02:05 ET2002.56
02:07 ET9002.53
02:09 ET4002.56
02:12 ET4002.56
02:14 ET14992.57
02:16 ET55192.54
02:18 ET64302.53
02:20 ET10022.53
02:21 ET20002.53
02:23 ET3002.53
02:25 ET8762.52
02:27 ET25002.52
02:30 ET58462.52
02:32 ET207632.48
02:34 ET2002.485
02:36 ET6982.48
02:39 ET55442.4701
02:41 ET2002.47
02:43 ET39722.47
02:45 ET1002.4899
02:50 ET24972.48
02:57 ET49802.5
03:01 ET3002.5
03:12 ET2952.5
03:14 ET1852.4797
03:15 ET33002.49
03:19 ET24832.4605
03:24 ET86722.52
03:26 ET88952.52
03:28 ET14962.5369
03:30 ET33002.5499
03:32 ET30002.5401
03:33 ET36002.5405
03:35 ET129512.48
03:44 ET8002.52
03:46 ET49872.46
03:48 ET22162.4667
03:50 ET4612.49
03:53 ET3002.48
04:00 ET69322.48
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCGTX
Cognition Therapeutics Inc
70.4M
-2.4x
---
United StatesMGTA
Magenta Therapeutics Inc
69.0M
-0.8x
---
United StatesELYM
Eliem Therapeutics Inc
71.7M
-1.5x
---
United StatesONCY
Oncolytics Biotech Inc
90.5M
-5.2x
---
United StatesGMTX
Gemini Therapeutics Inc
74.1M
-1.7x
---
United StatesPASG
Passage Bio Inc
66.0M
-0.4x
---
As of 2022-11-29

Company Information

Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It is focused on developing a pipeline of small molecule product candidates that targets the sigma-2 receptor (S2R) complex, a key regulator of the cellular damage response for diseases such as Alzheimer’s disease (AD), dry age-related macular degeneration (dry AMD), geographic atrophy (GA), and other conditions. Its lead product candidate, CT1812, an orally delivered, small molecule antagonist designed to penetrate the blood-brain and blood-retina barriers to the S2R complex, and through its modulation restores normal function of synapses, as well as critical cellular processes, such as autophagy, cholesterol biosynthesis, vesicle trafficking, progesterone signaling and receptor stabilization at the cell surface.

Contact Information

Headquarters
Suite 261, 2403 Sidney StreetPITTSBURGH, PA, United States 15203
Phone
412-770-1621
Fax
302-697-4597

Executives

Non-Executive Independent Chairman of the Board
Jack Khattar
President, Chief Executive Officer, Director
Lisa Ricciardi
Chief Financial Officer
Andrew Einhorn
Chief Medical Officer, Head of R&D
Anthony Caggiano
Independent Director
Aaron Fletcher

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$70.4M
Revenue (TTM)
$0.00
Shares Outstanding
27.6M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-1.03
Book Value
$2.31
P/E Ratio
-2.4x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.